APO Research
Talk to an analyst

APO RESEARCH · REPORT

Uric Acid-lowering Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Uric Acid-lowering Drugs Market Outlook and Growth Opportunities 2026

31 December 2025193 pages

Choose your research edition.

Industry ResearchUric Acid-lowering Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Uric Acid-lowering Drugs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Uric Acid-lowering Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Uric Acid-lowering Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Uric Acid-lowering Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Uric Acid-lowering Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Uric Acid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Uric Acid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Uric Acid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Uric Acid-lowering Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Uric Acid-lowering Drugs market include Takeda Pharmaceuticals, Teva, Sanwa Kagaku Kenkyusho, Sanofi, GSK, AstraZeneca, Towa Pharmaceutical, Toa Eiyo and Mylan Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Uric Acid-lowering Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Uric Acid-lowering Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Uric Acid-lowering Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Uric Acid-lowering Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Uric Acid-lowering Drugs Segment by Company

Takeda Pharmaceuticals

Teva

Sanwa Kagaku Kenkyusho

Sanofi

GSK

AstraZeneca

Towa Pharmaceutical

Toa Eiyo

Mylan Pharmaceuticals

Mochida Pharmaceutical

Lannett Company

Horizo​​n Therapeutics

Fuji Yakuhin

Uric Acid-lowering Drugs Segment by Type

Uric Acid Production Inhibitors

Uric Acid Dissolving Agents

Urate-stimulating Excretion Agents

Uric Acid-lowering Drugs Segment by Application

Hyperuricemia

Uric Acid Kidney Stones

Gout

Other

Uric Acid-lowering Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Uric Acid-lowering Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Uric Acid-lowering Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Uric Acid-lowering Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Uric Acid-lowering Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uric Acid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Uric Acid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uric Acid-lowering Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Uric Acid-lowering Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Uric Acid-lowering Drugs industry.

Chapter 3: Detailed analysis of Uric Acid-lowering Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Uric Acid-lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Uric Acid-lowering Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Uric Acid-lowering Drugs Industry Trends Table 2. Uric Acid-lowering Drugs Industry Drivers Table 3. Uric Acid-lowering Drugs Industry Opportunities and Challenges Table 4. Uric Acid-lowering Drugs Industry Restraints Table 5. Global Uric Acid-lowering Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Uric Acid-lowering Drugs Revenue Share by Company (2021-2026) Table 7. Global Uric Acid-lowering Drugs Sales Volume by Company (Units) & (2021-2026) Table 8. Global Uric Acid-lowering Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Uric Acid-lowering Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Uric Acid-lowering Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Uric Acid-lowering Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Uric Acid-lowering Drugs Company, Product Type & Application Table 13. Global Uric Acid-lowering Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Uric Acid-lowering Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Uric Acid Production Inhibitors Table 18. Significant Companies of Uric Acid Dissolving Agents Table 19. Significant Companies of Urate-stimulating Excretion Agents Table 20. Global Uric Acid-lowering Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 21. Global Uric Acid-lowering Drugs Sales Volume by Type (2021-2026) & (Units) Table 22. Global Uric Acid-lowering Drugs Sales Volume by Type (2027-2032) & (Units) Table 23. Global Uric Acid-lowering Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Uric Acid-lowering Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Uric Acid-lowering Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Uric Acid-lowering Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Uric Acid-lowering Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Uric Acid-lowering Drugs Sales Value Share by Type (2021-2026) Table 29. Global Uric Acid-lowering Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hyperuricemia Table 31. Significant Companies of Uric Acid Kidney Stones Table 32. Significant Companies of Gout Table 33. Significant Companies of Other Table 34. Global Uric Acid-lowering Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 35. Global Uric Acid-lowering Drugs Sales Volume by Application (2021-2026) & (Units) Table 36. Global Uric Acid-lowering Drugs Sales Volume by Application (2027-2032) & (Units) Table 37. Global Uric Acid-lowering Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Uric Acid-lowering Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Uric Acid-lowering Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Uric Acid-lowering Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Uric Acid-lowering Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Uric Acid-lowering Drugs Sales Value Share by Application (2021-2026) Table 43. Global Uric Acid-lowering Drugs Sales Value Share by Application (2027-2032) Table 44. Global Uric Acid-lowering Drugs Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 45. Global Uric Acid-lowering Drugs Sales by Region (2021-2026) & (Units) Table 46. Global Uric Acid-lowering Drugs Sales Market Share by Region (2021-2026) Table 47. Global Uric Acid-lowering Drugs Sales by Region (2027-2032) & (Units) Table 48. Global Uric Acid-lowering Drugs Sales Market Share by Region (2027-2032) Table 49. Global Uric Acid-lowering Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Uric Acid-lowering Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Uric Acid-lowering Drugs Sales Value Share by Region (2021-2026) Table 52. Global Uric Acid-lowering Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Uric Acid-lowering Drugs Sales Value Share by Region (2027-2032) Table 54. Global Uric Acid-lowering Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Uric Acid-lowering Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Uric Acid-lowering Drugs Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 57. Global Uric Acid-lowering Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Uric Acid-lowering Drugs Sales by Country (2021-2026) & (Units) Table 59. Global Uric Acid-lowering Drugs Sales Market Share by Country (2021-2026) Table 60. Global Uric Acid-lowering Drugs Sales by Country (2027-2032) & (Units) Table 61. Global Uric Acid-lowering Drugs Sales Market Share by Country (2027-2032) Table 62. Global Uric Acid-lowering Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Uric Acid-lowering Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Uric Acid-lowering Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Uric Acid-lowering Drugs Sales Value Market Share by Country (2027-2032) Table 66. Takeda Pharmaceuticals Company Information Table 67. Takeda Pharmaceuticals Business Overview Table 68. Takeda Pharmaceuticals Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Takeda Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio Table 70. Takeda Pharmaceuticals Recent Development Table 71. Teva Company Information Table 72. Teva Business Overview Table 73. Teva Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Teva Uric Acid-lowering Drugs Product Portfolio Table 75. Teva Recent Development Table 76. Sanwa Kagaku Kenkyusho Company Information Table 77. Sanwa Kagaku Kenkyusho Business Overview Table 78. Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Product Portfolio Table 80. Sanwa Kagaku Kenkyusho Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Sanofi Uric Acid-lowering Drugs Product Portfolio Table 85. Sanofi Recent Development Table 86. GSK Company Information Table 87. GSK Business Overview Table 88. GSK Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. GSK Uric Acid-lowering Drugs Product Portfolio Table 90. GSK Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Uric Acid-lowering Drugs Product Portfolio Table 95. AstraZeneca Recent Development Table 96. Towa Pharmaceutical Company Information Table 97. Towa Pharmaceutical Business Overview Table 98. Towa Pharmaceutical Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Towa Pharmaceutical Uric Acid-lowering Drugs Product Portfolio Table 100. Towa Pharmaceutical Recent Development Table 101. Toa Eiyo Company Information Table 102. Toa Eiyo Business Overview Table 103. Toa Eiyo Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Toa Eiyo Uric Acid-lowering Drugs Product Portfolio Table 105. Toa Eiyo Recent Development Table 106. Mylan Pharmaceuticals Company Information Table 107. Mylan Pharmaceuticals Business Overview Table 108. Mylan Pharmaceuticals Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Mylan Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio Table 110. Mylan Pharmaceuticals Recent Development Table 111. Mochida Pharmaceutical Company Information Table 112. Mochida Pharmaceutical Business Overview Table 113. Mochida Pharmaceutical Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Mochida Pharmaceutical Uric Acid-lowering Drugs Product Portfolio Table 115. Mochida Pharmaceutical Recent Development Table 116. Lannett Company Company Information Table 117. Lannett Company Business Overview Table 118. Lannett Company Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Lannett Company Uric Acid-lowering Drugs Product Portfolio Table 120. Lannett Company Recent Development Table 121. Horizo​​n Therapeutics Company Information Table 122. Horizo​​n Therapeutics Business Overview Table 123. Horizo​​n Therapeutics Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Horizo​​n Therapeutics Uric Acid-lowering Drugs Product Portfolio Table 125. Horizo​​n Therapeutics Recent Development Table 126. Fuji Yakuhin Company Information Table 127. Fuji Yakuhin Business Overview Table 128. Fuji Yakuhin Uric Acid-lowering Drugs Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Fuji Yakuhin Uric Acid-lowering Drugs Product Portfolio Table 130. Fuji Yakuhin Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Uric Acid-lowering Drugs Distributors List Table 134. Uric Acid-lowering Drugs Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Uric Acid-lowering Drugs Product Image Figure 2. Global Uric Acid-lowering Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Uric Acid-lowering Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Uric Acid-lowering Drugs Sales (2021-2032) & (Units) Figure 5. Global Uric Acid-lowering Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Uric Acid-lowering Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Uric Acid Production Inhibitors Image Figure 10. Uric Acid Dissolving Agents Image Figure 11. Urate-stimulating Excretion Agents Image Figure 12. Global Uric Acid-lowering Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 13. Global Uric Acid-lowering Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Uric Acid-lowering Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Uric Acid-lowering Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Uric Acid-lowering Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Uric Acid-lowering Drugs Sales Value Share by Type (2021-2032) Figure 18. Hyperuricemia Image Figure 19. Uric Acid Kidney Stones Image Figure 20. Gout Image Figure 21. Other Image Figure 22. Global Uric Acid-lowering Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 23. Global Uric Acid-lowering Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Uric Acid-lowering Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Uric Acid-lowering Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Uric Acid-lowering Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Uric Acid-lowering Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Uric Acid-lowering Drugs Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 29. Global Uric Acid-lowering Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Uric Acid-lowering Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Uric Acid-lowering Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Uric Acid-lowering Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Uric Acid-lowering Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Uric Acid-lowering Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Uric Acid-lowering Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Uric Acid-lowering Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Uric Acid-lowering Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Uric Acid-lowering Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Uric Acid-lowering Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Uric Acid-lowering Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Uric Acid-lowering Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Uric Acid-lowering Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Uric Acid-lowering Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Uric Acid Production Inhibitors
  • Uric Acid Dissolving Agents
  • Urate-stimulating Excretion Agents
Applications
  • Hyperuricemia
  • Uric Acid Kidney Stones
  • Gout
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Teva
  • Sanwa Kagaku Kenkyusho
  • Sanofi
  • GSK
  • AstraZeneca
  • Towa Pharmaceutical
  • Toa Eiyo
  • Mylan Pharmaceuticals
  • Mochida Pharmaceutical
  • Lannett Company
  • Horizo​​n Therapeutics
  • Fuji Yakuhin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Uric Acid-lowering Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Uric Acid-lowering Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Uric Acid-lowering Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Uric Acid-lowering Drugs Market Dynamics
  1. 2.1 Uric Acid-lowering Drugs Industry Trends
  2. 2.2 Uric Acid-lowering Drugs Industry Drivers
  3. 2.3 Uric Acid-lowering Drugs Industry Opportunities and Challenges
  4. 2.4 Uric Acid-lowering Drugs Industry Restraints
3 Uric Acid-lowering Drugs Market by Company
  1. 3.1 Global Uric Acid-lowering Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Uric Acid-lowering Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Uric Acid-lowering Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Uric Acid-lowering Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Uric Acid-lowering Drugs Company Ranking (2024-2026)
  6. 3.6 Global Uric Acid-lowering Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Uric Acid-lowering Drugs Company Product Type and Application
  8. 3.8 Global Uric Acid-lowering Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Uric Acid-lowering Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Uric Acid-lowering Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Uric Acid-lowering Drugs Market by Type
  1. 4.1 Uric Acid-lowering Drugs Type Introduction
  2. 4.1.1 Uric Acid Production Inhibitors
  3. 4.1.2 Uric Acid Dissolving Agents
  4. 4.1.3 Urate-stimulating Excretion Agents
  5. 4.2 Global Uric Acid-lowering Drugs Sales Volume by Type
  6. 4.2.1 Global Uric Acid-lowering Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Uric Acid-lowering Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Uric Acid-lowering Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Uric Acid-lowering Drugs Sales Value by Type
  10. 4.3.1 Global Uric Acid-lowering Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Uric Acid-lowering Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Uric Acid-lowering Drugs Sales Value Share by Type (2021-2032)
5 Uric Acid-lowering Drugs Market by Application
  1. 5.1 Uric Acid-lowering Drugs Application Introduction
  2. 5.1.1 Hyperuricemia
  3. 5.1.2 Uric Acid Kidney Stones
  4. 5.1.3 Gout
  5. 5.1.4 Other
  6. 5.2 Global Uric Acid-lowering Drugs Sales Volume by Application
  7. 5.2.1 Global Uric Acid-lowering Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Uric Acid-lowering Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Uric Acid-lowering Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Uric Acid-lowering Drugs Sales Value by Application
  11. 5.3.1 Global Uric Acid-lowering Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Uric Acid-lowering Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Uric Acid-lowering Drugs Sales Value Share by Application (2021-2032)
6 Uric Acid-lowering Drugs Regional Sales and Value Analysis
  1. 6.1 Global Uric Acid-lowering Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Uric Acid-lowering Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Uric Acid-lowering Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Uric Acid-lowering Drugs Sales by Region (2027-2032)
  5. 6.3 Global Uric Acid-lowering Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Uric Acid-lowering Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Uric Acid-lowering Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Uric Acid-lowering Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Uric Acid-lowering Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Uric Acid-lowering Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Uric Acid-lowering Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Uric Acid-lowering Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Uric Acid-lowering Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Uric Acid-lowering Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Uric Acid-lowering Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Uric Acid-lowering Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Uric Acid-lowering Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Uric Acid-lowering Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Uric Acid-lowering Drugs Sales Value Share by Country, 2025 VS 2032
7 Uric Acid-lowering Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Uric Acid-lowering Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Uric Acid-lowering Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Uric Acid-lowering Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Uric Acid-lowering Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Uric Acid-lowering Drugs Sales by Country (2027-2032)
  6. 7.4 Global Uric Acid-lowering Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Uric Acid-lowering Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Uric Acid-lowering Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Uric Acid-lowering Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Uric Acid-lowering Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Uric Acid-lowering Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Uric Acid-lowering Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanwa Kagaku Kenkyusho
  14. 8.3.1 Sanwa Kagaku Kenkyusho Company Information
  15. 8.3.2 Sanwa Kagaku Kenkyusho Business Overview
  16. 8.3.3 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Product Portfolio
  18. 8.3.5 Sanwa Kagaku Kenkyusho Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Uric Acid-lowering Drugs Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GSK Uric Acid-lowering Drugs Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Uric Acid-lowering Drugs Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Towa Pharmaceutical
  38. 8.7.1 Towa Pharmaceutical Company Information
  39. 8.7.2 Towa Pharmaceutical Business Overview
  40. 8.7.3 Towa Pharmaceutical Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Towa Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
  42. 8.7.5 Towa Pharmaceutical Recent Developments
  43. 8.8 Toa Eiyo
  44. 8.8.1 Toa Eiyo Company Information
  45. 8.8.2 Toa Eiyo Business Overview
  46. 8.8.3 Toa Eiyo Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Toa Eiyo Uric Acid-lowering Drugs Product Portfolio
  48. 8.8.5 Toa Eiyo Recent Developments
  49. 8.9 Mylan Pharmaceuticals
  50. 8.9.1 Mylan Pharmaceuticals Company Information
  51. 8.9.2 Mylan Pharmaceuticals Business Overview
  52. 8.9.3 Mylan Pharmaceuticals Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mylan Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
  54. 8.9.5 Mylan Pharmaceuticals Recent Developments
  55. 8.10 Mochida Pharmaceutical
  56. 8.10.1 Mochida Pharmaceutical Company Information
  57. 8.10.2 Mochida Pharmaceutical Business Overview
  58. 8.10.3 Mochida Pharmaceutical Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Mochida Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
  60. 8.10.5 Mochida Pharmaceutical Recent Developments
  61. 8.11 Lannett Company
  62. 8.11.1 Lannett Company Company Information
  63. 8.11.2 Lannett Company Business Overview
  64. 8.11.3 Lannett Company Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Lannett Company Uric Acid-lowering Drugs Product Portfolio
  66. 8.11.5 Lannett Company Recent Developments
  67. 8.12 Horizo​​n Therapeutics
  68. 8.12.1 Horizo​​n Therapeutics Company Information
  69. 8.12.2 Horizo​​n Therapeutics Business Overview
  70. 8.12.3 Horizo​​n Therapeutics Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Horizo​​n Therapeutics Uric Acid-lowering Drugs Product Portfolio
  72. 8.12.5 Horizo​​n Therapeutics Recent Developments
  73. 8.13 Fuji Yakuhin
  74. 8.13.1 Fuji Yakuhin Company Information
  75. 8.13.2 Fuji Yakuhin Business Overview
  76. 8.13.3 Fuji Yakuhin Uric Acid-lowering Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Fuji Yakuhin Uric Acid-lowering Drugs Product Portfolio
  78. 8.13.5 Fuji Yakuhin Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Uric Acid-lowering Drugs Value Chain Analysis
  2. 9.1.1 Uric Acid-lowering Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Uric Acid-lowering Drugs Sales Mode & Process
  6. 9.2 Uric Acid-lowering Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Uric Acid-lowering Drugs Distributors
  9. 9.2.3 Uric Acid-lowering Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst